Guardant Health Tops Q4 Revenue Forecast
Guardant Health (NASDAQ:GH), a leader in precision oncology testing, announced its fourth-quarter results on Feb. 20. Total revenue rose 30% year over year to $201.8 million, outpacing analysts' consensus estimates of $192 million. On the bottom line, it booked a non-GAAP loss of $0.62 per share, narrower than the expected loss of $0.75 per share. Despite advancements and positive results, increased operating expenses, mainly due to R and sales costs, resulted in a net loss of $111 million.
Source: Analysts' estimates for the quarter provided by FactSet.
Guardant Health specializes in precision oncology, developing advanced blood tests for cancer detection and management. The core of its business lies in liquid biopsies for both advanced-stage and early cancer detection. The company is devoting significant attention to product innovation and strategic partnerships to enhance its research capabilities and broaden its market access. Its ability to secure payer reimbursement for its products is pivotal to its financial success, so ongoing efforts to engage with Medicare and commercial payers are crucial.
Source Fool.com
